Portrait of ependymoma recurrence in children: Biomarkers of tumor progression identified by dual- color microarray-based gene expression analysis

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Peyre, Matthieu ^a   Commo, Frédéric ^a   Dantas Barbosa, Carmela ^a   Andreiuolo, Felipe ^a   Puget, Stéphanie ^a,b   Lacroix, Ludovic ^a   Drusch, Françoise ^a   Scott, Véronique ^a   Varlet, Pascale ^c   Mauguen, Audrey ^a   Dessen, Philippe ^a   Lazar, Vladimir ^a   Vassal, Gilles ^a   Grill, Jacques ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; CD133 ANTIGEN; CHROMOSOME PROTEIN; DNA; KINESIN; METALLOTHIONEIN III; NOTCH RECEPTOR; PROTEIN ASPM; PROTEIN KIF11; UNCLASSIFIED DRUG; WNT PROTEIN; METALLOTHIONEIN; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CENTROMERE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; EPENDYMOMA; GENE CLUSTER; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOSS; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NERVE CELL DIFFERENTIATION; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; RECURRENT CANCER; UPREGULATION; DISEASE COURSE; FEMALE; FOLLOW UP; GENETICS; INFANT; INSTRUMENTATION; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE;

CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; EPENDYMOMA; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; METALLOTHIONEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 77958536805     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012932     Document Type: Article

References (77)

1. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, et al. (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8: 323-335.
2. McLendon RE, Wiestler OD, Kros JM (2007) Ependymoma. In: Louis DN, ed. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC. pp 74-78.
3. Peris-Bonet R, Martinez-Garcia C, Lacour B, Petrovich S, Giner-Ripoll B, et al. (2006) Childhood central nervous system tumours-incidence and survival in Europe (1978-1997): report from Automated Childhood Cancer Information System project. Eur J Cancer 42: 2064-2080.
4. Bouffet E, Perilongo G, Canete A, Massimino M (1998) Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30: 319-329; discussion 329-331.
5. Wetjen N, Raffel C (2006) Ependymomas. In: Tonn JC WM, Rutka JT, Grossman SA, eds. Neuro-Oncology of CNS tumors. Berlin Heidelberg: Springer. pp 453-460.
6. Perilongo G, Massimino M, Sotti G, Belfontali T, Masiero L, et al. (1997) Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group. Med Pediatr Oncol 29: 79-85.
7. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, et al. (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10: 258-266.
8. van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, Sainte-Rose C, Zerah M, et al. (2002) Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 97: 827-835.
9. Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, et al. (2000) Prognostic factors in intracranial ependymomas in children. J Neurosurg 93: 605-613.
10. Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, et al. (2001) Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19: 1288-1296.
11. Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, et al. (2007) Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8: 696-705.
12. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, et al. (2006) Identification of tumor-specific molecular signatures in intracranial ependymo- ma and association with clinical characteristics. J Clin Oncol 24: 5223-5233.
13. Kilday JP, Rahman R, Dyer S, Ridley L, Lowe J, et al. (2009) Pediatric ependymoma: biological perspectives. Mol Cancer Res 7: 765-786.
14. Palm T, Figarella-Branger D, Chapon F, Lacroix C, Gray F, et al. (2009) Expression profiling of ependymomas unravels localization and tumor gradespecific tumorigenesis. Cancer 115: 3955-3968.
15. Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-Demasters BK, et al. (2009) Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol 183: 7428-7440.
16. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, et al. (2010) Molecular Staging of Intracranial Ependymoma in Children and Adults. J Clin Oncol 28: 3182-3190.
17. Hamilton RL, Pollack IF (1997) The molecular biology of ependymomas. Brain Pathol 7: 807-822.
18. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, et al. (2006) Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 66: 10339-10348.
19. Hirose Y, Aldape K, Bollen A, James CD, Brat D, et al. (2001) Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 158: 1137-1143.
20. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, et al. (2006) Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12: 2070-2079.
21. Sowar K, Straessle J, Donson AM, Handler M, Foreman NK (2006) Predicting which children are at risk for ependymoma relapse. J Neurooncol 78: 41-46.
22. Suarez-Merino B, Hubank M, Revesz T, Harkness W, Hayward R, et al. (2005) Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 7: 20-31.
23. Tabori U, Ma J, Carter M, Zielenska M, Rutka J, et al. (2006) Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 24: 1522-1528.
24. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Mauro A, et al. (2001) CDKN2A/p16 in ependymomas. J Neurooncol 54: 9-13.
25. Alonso ME, Bello MJ, Arjona D, Gonzalez-Gomez P, Lomas J, et al. (2002) Analysis of the NF2 gene in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 134: 1-5.
26. Schneider D, Monoranu CM, Huang B, Rutkowski S, Gerber NU, et al. (2009) Pediatric supratentorial ependymomas show more frequent deletions on chromosome 9 than infratentorial ependymomas: a microsatellite analysis. Cancer Genet Cytogenet 191: 90-96.
27. Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, et al. (2008) Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 10: 675-689.
28. Snuderl M, Chi SN, De Santis SM, Stemmer-Rachamimov AO, Betensky RA, et al. (2008) Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol 67: 911-920.
29. Lukashova-v Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, et al. (2007) Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 113: 325-337.
30. Puget S, Grill J, Valent A, Bieche I, Dantas-Barbosa C, et al. (2009) Candidate Genes on Chromosome 9q33-34 Involved in the Progression of Childhood Ependymomas. J Clin Oncol 27: 1884-1892.
31. Lu R, Lee GC, Shultz M, Dardick C, Jung K, et al. (2008) Assessing probespecific dye and slide biases in two-color microarray data. BMC Bioinformatics 9: 314.
32. Martin-Magniette ML, Aubert J, Cabannes E, Daudin JJ (2005) Evaluation of the gene-specific dye bias in cDNA microarray experiments. Bioinformatics 21: 1995-2000.
33. t Hoen PA, Turk R, Boer JM, Sterrenburg E, de Menezes RX, et al. (2004) Intensity-based analysis of two-colour microarrays enables efficient and flexible hybridization designs. Nucleic Acids Res 32: e41.
34. Smith E, Drew PA, Tian ZQ, De Young NJ, Liu JF, et al. (2005) Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 4: 42.
35. Grill J, Avet-Loiseau H, Lellouch-Tubiana A, Sevenet N, Terrier-Lacombe MJ, et al. (2002) Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet 136: 121-125.
36. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, et al. (2007) Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 67: 890-900.
37. L'Esperance S, Popa I, Bachvarova M, Plante M, Patten N, et al. (2006) Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 29: 5-24.
38. Liu CJ, Liu TY, Kuo LT, Cheng HW, Chu TH, et al. (2008) Differential gene expression signature between primary and metastatic head and neck squamous cell carcinoma. J Pathol 214: 489-497.
39. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, et al. (2007) Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 121: 2005-2012.
40. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
41. Sousa JF, Espreafico EM (2008) Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer 8: 19.
42. Michiels S, Koscielny S, Hill C (2007) Interpretation of microarray data in cancer. Br J Cancer 96: 1155-1158.
43. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521.
44. Corson TW, Gallie BL (2006) KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 119: 1088-1094.
45. Corson TW, Huang A, Tsao MS, Gallie BL (2005) KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24: 4741-4753.
46. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, et al. (2007) KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 13: 3229-3234.
47. Bond J, Roberts E, Mochida GH, Hampshire DJ, Scott S, et al. (2002) ASPM is a major determinant of cerebral cortical size. Nat Genet 32: 316-320.
48. Muller C, Gross D, Sarli V, Gartner M, Giannis A, et al. (2007) Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother Pharmacol 59: 157-164.
49. Chin GM, Herbst R (2006) Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol Cancer Ther 5: 2580-2591.
50. Valensin S, Ghiron C, Lamanna C, Kremer A, Rossi M, et al. (2009) KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain? BMC Cancer 9: 196.
51. Cherian MG, Jayasurya A, Bay BH (2003) Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209.
52. Yap X, Tan HY, Huang J, Lai Y, Yip GW, et al. (2008) Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol 217: 563-570.
53. Satoh M, Cherian MG, Imura N, Shimizu H (1994) Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 54: 5255-5257.
54. Sato M, Bremner I (1993) Oxygen free radicals and metallothionein. Free Radic Biol Med 14: 325-337.
55. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M (1991) The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 7: 337-347.
56. Hidalgo J, Aschner M, Zatta P, Vasak M (2001) Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 55: 133-145.
57. Garrett SH, Sens MA, Todd JH, Somji S, Sens DA (1999) Expression of MT-3 protein in the human kidney. Toxicol Lett 105: 207-214.
58. Ebadi M, Iversen PL, Hao R, Cerutis DR, Rojas P, et al. (1995) Expression and regulation of brain metallothionein. Neurochem Int 27: 1-22.
59. Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, et al. (1994) Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33: 7250-7259.
60. Thirumoorthy N, Manisenthil Kumar KT, Shyam Sundar A, Panayappan L, Chatterjee M (2007) Metallothionein: an overview. World J Gastroenterol 13: 993-996.
61. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, et al. (2008) Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 88: 474-481.
62. Deng D, El-Rifai W, Ji J, Zhu B, Trampont P, et al. (2003) Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 24: 25-29.
63. Dalgin GS, Drever M, Williams T, King T, DeLisi C, et al. (2008) Identification of novel epigenetic markers for clear cell renal cell carcinoma. J Urol 180: 1126-1130.
64. Zhong S, Fields CR, Su N, Pan YX, Robertson KD (2007) Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26: 2621-2634.
65. Henrique R, Jeronimo C, Hoque MO, Nomoto S, Carvalho AL, et al. (2005) MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 14: 1274-1278.
66. Korshunov A, Sycheva R, Timirgaz V, Golanov A (1999) Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 45: 219-227.
67. Ghoshal K, Datta J, Majumder S, Bai S, Dong X, et al. (2002) Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol 22: 8302-8319.
68. Haq F, Mahoney M, Koropatnick J (2003) Signaling events for metallothionein induction. Mutat Res 533: 211-226.
69. Kramer KK, Liu J, Choudhuri S, Klaassen CD (1996) Induction of metallothionein mRNA and protein in murine astrocyte cultures. Toxicol Appl Pharmacol 136: 94-100.
70. Kramer KK, Zoelle JT, Klaassen CD (1996) Induction of metallothionein mRNA and protein in primary murine neuron cultures. Toxicol Appl Pharmacol 141: 1-7.
71. Wei H, Desouki MM, Lin S, Xiao D, Franklin RB, et al. (2008) Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 7: 7.
72. Voulgari A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90.
73. Rome C, Loiseau H, Arsaut J, Roullot V, Couillaud F (2006) Diversity of contactin mRNA in human brain tumors. Mol Carcinog 45: 774-785.
74. Bizzoca A, Corsi P, Gennarini G (2009) The mouse F3/contactin glycoprotein: Structural features, functional properties and developmental significance of its regulated expression. Cell Adh Migr 3: 53-63.
75. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
76. Colin C, Virard I, Baeza N, Tchoghandjian A, Fernandez C, et al. (2007) Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathol Appl Neurobiol 33: 431-439.
77. Qi Y, Cai J, Wu Y, Wu R, Lee J, et al. (2001) Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development 128: 2723-2733.